37 results on '"A.M.M. Eggermont"'
Search Results
2. 804P Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
3. LBA44 Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
4. 76P Safety profile of adjuvant pembrolizumab (pembro) in melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC): Pooled analysis of phase III clinical trials
5. Risk stratification of sentinel node positive melanoma patients defines surgical management and adjuvant therapy treatment considerations
6. Management of psychiatric adverse events with immunotherapy with interferon-alfa
7. WHAT CAN WE LEARN REGARDING IMMUNOTHERAPY FROM MALIGNANT MELANOMA
8. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: A corollary study to EORTC trial 18952
9. Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases
10. Monitoring stage-specific trends in melanoma incidence across Europe reveals the need for more complete information on diagnostic characteristics
11. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial
12. Angiostatin generation by human tumor cell lines: Involvement of plasminogen activators
13. Strategy of the EORTC-MCG trial programme for adjuvant treatment of moderate-risk and high-risk melanoma
14. VWF release and platelet aggregation in human melanoma after perfusion with TNFα
15. Intraperitoneal Chemotherapy and Immunotherapy
16. Up-to-date survival estimates and historical trends of cutaneous malignant melanoma in the south-east of The Netherlands
17. Influence of pegylated interferon-alpha therapy on plasma levels of citrulline and arginine in melanoma patients
18. Rising trends in the incidence of and mortality from cutaneous melanoma in the Netherlands: a Northwest to Southeast gradient?
19. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity
20. Ultrasound-guided FNAC prior to SLNB in MM patients: SN-positive identification rate with FNAC is high, reduces the need for SNLB, but is not further improved by RT-PCR of the aspirate
21. Isolated limb perfusion of an irradiated foot with tumor necrosis factor, interferon, and melphalan
22. Adjuvant regional isolated perfusion with melphalan for patients with Clark V melanoma of the extremities
23. 127 INVITED Translational reseach is key in clinical trials: MD/PhDs in the driving seat …
24. 3BA Reduction of need for operative sentinel node procedure in melanoma patients: fifty percent identification rate of sentinel node positivity by ultrasound (US)- guided fine needle aspiration cytology (FNAC) in 400 consecutive patients
25. Role of ultrasound (US) and US-guided fine needle aspiration cytology (US-FNAC) prior to sentinel lymph node biopsy (SLNB) in 500 melanoma patients: Reduction of need for SNLB by high US-FNAC SN positive identification rate
26. Introduction
27. Population-based survival of melanoma: much better survival rates than estimated by the AJCC
28. Changes in microRNAs spectrum during melanoma progression
29. 348 Adjuvant therapy in melanoma
30. Isolated limb perfusion: Lessons from preclinical models
31. Regional application of cytokines: Experience with various clinical protocols
32. A randomized trial of IFNα and IL-2 ± cisplatinum in advanced melanoma — a preliminary analysis
33. Plasma Activity of Prolyl Endopeptidase in Relation to Psychopathology During Immunotherapy with IFN-αin Patients with Renal Cell Carcinoma.
34. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
35. Serum Activity of Prolyl Endopeptidase, but Not of Dipeptidyl Peptidase IV, Is Decreased by Immunotherapy with IFN-α in High-Risk Melanoma Patients.
36. Isolated limb perfusion (ILP) with high dose TNF-α, gamma-IFN and melphalan in patients with irresectable soft tissue sarcomas: A highly effective limb saving procedure
37. Regional infusions and perfusions with cytokines
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.